Cytokinetics, Inc. (CYTK) fell 12.98% due to FDA delay for heart treatment approval

From Yahoo Finance: 2025-05-03 06:37:00

Wall Street indices ended the week strong on better-than-expected non-farm payrolls and corporate earnings. Nasdaq up 1.51%, S&P 500 up 1.47%, Dow Jones up 1.39%. Despite market optimism, 10 firms saw declines due to poor Q1 earnings. Cytokinetics, Inc. (CYTK) fell 12.98% on FDA delay for heart treatment approval. Aficamten under review for heart disorder. CYTK confident in drug’s benefit-risk profile. CYTK ranks 3rd worst performer. AI stocks offer higher returns in shorter time frame. Check out report on cheapest AI stock for promising investment.



Read more at Yahoo Finance: Why Cytokinetics, Inc. (CYTK) Went Down On Friday